drug effect impact moat valuat esg risk
icer presid give perspect drug valu polit risk
go away like near-term
icer presid steven pearson
effect drug price
icer histori cost-effect
determin show mix result
conduct analyst govern
code ethics/cod conduct polici
secur trade polici equival
invest research polici inform
regard conflict interest pleas visit
icer presid steven pearson effect drug price
value-bas reimburs standard intern market year use
cost-effect studi part analysi firm price risk valuat moat rate
feb held confer call dr steven pearson founder presid institut
clinic econom review icer discuss firm work cost-effect brand
drug icer cost-effect analysi grown power past decad drive price
decis drug firm payor coverag decis
effect window price esg risk drug firm
assess esg risk brand drug firm work sustainalyt
determin price risk key esg issu background pleas see healthcar
observ titl esg risk affect moat valuat pharma morningstar
sustainalyt offer complementari methodolog dramat differ intern drug
price key risk futur drug price view see cost effect core
piec assess potenti brand drug price pressur
 healthcar system valu drug premium nation partli lack
nation insur system overarch budget price benchmark drug
reimport odd could difficult implement view senat
prescript drug price reduct act like near-term drug polici reform still
less probabl could reduc brand drug industri sale
follow discuss comfort bullish assumpt gilead
filgotinib immunolog biomarin val-rox hemophilia gene therapi concern
novarti inclisiran roch risdiplam could erod price cholesterol-low spinal
muscular atrophi follow launch potenti price disrupt oral oncolog market
radar exampl competit btk inhibitor market
under-valued pharma biotech firm lower esg price risk
price data feb
page
drug effect impact moat valuat esg risk februari import disclosur end report
convers drug price valu
whether drug appear cost-effect standard part value-bas reimburs
intern market year unit kingdom nation institut
excel creat help nation health servic negoti drug price
lag market cost-effect research institut clinic econom review --
icer -- gain credibl power independ privat organ assess cost
effect decis icer make impact drug price insur compani
drug compani right medicar reli qualiti adjust life year
reimburs decis part afford act medicaid commerci market
start incorpor sort cost-effect analysi
convers cover background icer cost-effect methodolog
becom critic payor drug firm also talk key therapeut
area exampl discuss futur potenti drug polici reform
put number drug valu patient challeng calcul improv
one central measur cost effect brand drug date drug
extend patient life improv patient qualiti life drug ad patient
valu one qali one year healthi person set level deem appropri
note cost effect part valu assess may priorit
market like england icer first look clinic effect report cost
effect take step tri captur long-term valu treat patient new
medicin effect compar rel effect long term build simul
base two thing translat short-term data patient outcom happen
cours ill long run make assumpt trajectori ill
depend whether patient treat new medicin
icer threshold price base societi will pay
look cost effect drug year much lower qali threshold
icer drug gener consid cost-effect price gbp per
qali cost-effect price gbp icer set higher
threshold price gener per qali american
frustrat fact carri outsiz portion global drug cost estim net drug
price roughli doubl cost europ cost-effect threshold appear support
differ confirm note england process base
budget opportun cost approach suggest lower threshold spend much
improv health one area may lead neg effect part system
formal budget beyond program like medicaid figur societi will
pay drug requir differ method accord best research look
page
drug effect impact moat valuat esg risk februari import disclosur end report
effect rise premium whether american opt insur relat impact
patient mortal environ sacrif healthcar coverag research get
closer per qali level enough patient drop insur
lose live gain cover new treatment icer use slightli higher rang
analys
icer power grow payor use cost-effect research ad-hoc structur basi
icer design cost effect necessari reimburs payor appear
use icer analys negoti drug firm survey contract research organ icon
publish septemb show payor increasingli like use icer analysi
decis survey payor like extrem like follow icer cost-effect
guidanc versu manufactur respond icer guidanc
launch cholesterol-low antibodi annual
competitor regeneron/sanofi negoti steep price discount repatha praluent
regeneron sanofi lower price praluent keep within icer recommend drug
manufactur also price anticip icer cost-effect scrutini exampl
price migrain drug aimovig -- also enter competit market two similar novel therapi
approach market -- within icer recommend guidanc
see rapid growth specialti drug cost one driver payor interest
research well rapid growth hepat drug sale launch gilead sovaldi
harvoni icer work preserv independ payor use icer analysi
anchor fair price might negoti drug firm icer clinic effect
rate detail report analys free public payor payor use
supplement analysi payor use report ad-hoc basi support argument
whether given drug overpr give power behind negoti drug
manufactur structur use icer report becom part formulari benefit design
help determin tier step therapi earlier phase tool discourag use
less cost-effect therapi encourag use cost-effect therapi use icer
benefit design employe price come top icer rang
plan option declar non-cov benefit stir question restrict
access move slowli process meant lead exclus better
negoti ultim expand access cost pressur continu increas expect
structur approach use icer work
solid endpoint help secur icer review competit landscap price
overal chanc secur posit review icer seem improv right trial
endpoint ultim competit landscap key determin price exampl
lilli novo work high-dos treatment gip/glp combin could
improv upon efficaci drug like novo new oral therapi rybelsu list price
page
drug effect impact moat valuat esg risk februari import disclosur end report
rybelsu similar inject list price net price still process
negoti think novo could justifi price premium better review pipelin therapi
current similar review rybelsu cheaper oral therapi jardianc could make
difficult justifi net premium rybelsu novo move oral diabet market
negoti payor
note drug improv efficaci versu anoth approv drug
view cost effect simpl think firm justifi higher price
simpl answer drug firm secur good review certain surrog long-term efficaci
like progression-fre surviv cancer cholesterol lower cardiovascular diseas give
icer confid drug short-term effect trial could translat long-term
outcom see select right endpoint critic process inclus qualiti life
survey part trial design appear help icer analysi
ultim price drug obtain market also relat competit landscap
may relat fundament benefit patient exampl drug slightli
better standard care price standard care import could rang
specialti brand drug significantli less gener drug one-tim limit
cours treatment like sanofi multipl sclerosi therapi lemtrada novarti spinal muscular atrophi
gene therapi zolgensma gener much easier time show cost effect chronic
treatment altern drug receiv gener favor review icer see
page sma market
time firm short-term data new product launch long-
term outcom data exampl icer plan review esperion bempedo acid year
cholesterol lower short-term data product make cost effect
potenti difficult compar establish point addit novarti
inclisiran could reach market end cv outcom data like
think inclisiran look similar efficaci safeti establish therapi
sanofi/regeneron base initi data concern exist lack outcom data
launch could delay uptak addit novo nordisk think gener justifi net price
therapi blame icer decis assign net health benefit new oral therapi
rybelsu lilli oral therapi jardianc take long-term complic diseas
account
howev convers reassur us icer will make call cost
effect surrog data clear link endpoint long-term
outcom think bode well uptak drug surrog data field valu
surrog establish like cholesterol lower mortal could weigh potenti
growth exist inhibitor repatha praluent inclisiran launch area less
establish surrog case note icer unabl determin cost
page
drug effect impact moat valuat esg risk februari import disclosur end report
effect sarepta eteplirsen exondi golodirsen vyondi duchenn muscular
dystrophi see clear link biochem chang clinic outcom
drug high price impli effect near level cure
icer also move formal updat everi new report determin whether
anyth chang analysi new data gather whether old analysi still valid
also pilot process two-year updat drug approv acceler approv
system fda broadli made formal updat past report
market still drug receiv poor cost-effect rate due
rebat wall variabl patient respons medicin
tnf-alpha humira one promin exampl drug appear cost-
effect mani multipl sclerosi ms drug look cost-effect fact ms market
egregi price industri measur cost effect also
enorm estim price discrep intern market drug abl take
signific price increas annual despit poor mark cost effect roch ocrevu stand
one therapi actual look cost effect least broader relaps remit
ms market exhibit exampl icer posit neg cost-effect
note reason drug continu see strong price cost-effect
analysi compet drug attack high castl first hard payor restrict coverag
one tnf-alpha rheumatoid arthriti doctor need case patient respond
patient variabl respons rate note true ms rheumatoid arthriti
ra auto-immun diseas also see bundl rebat anoth issu
drug multipl indic drug firm contract payor across indic
creat wall innov drug lead inclin price slope humira
compet drug landscap payor could requir patient switch differ drug
humira societi gener want enforc switch effect therapi
area variabl patient respons sometim competit landscap put pressur pharmaci
benefit manag explor tighter manag cost area like oncolog note
tight manag reput clinic risk
sever exampl drug gone icer review process gain
posit review would creat heavi financi burden patient healthcar system
use wide includ cardiometabol drug like bayer/j xarelto pfizer/bristol eliqui
cholesterol-low drug repatha praluent hepat therapi gilead
alzheim diseas treatment could ad list success aducanumab
file year overal seen drug increasingli launch lower price gain strong
access histor common launch higher price lower price time
restrict access weigh sale growth
page
drug effect impact moat valuat esg risk februari import disclosur end report
note drug great long-term cost effect million seek treatment
way payor manag budget short-term crush whether mean
price reduc need effici healthcar system bailout like
medicaid va program hepat rush unclear practic payor want
lower price matter valu sometim accept higher price tightli manag
access uptak true well -- nh institut budget impact threshold gbp
million per year -- drug fit second level review nh even gave
drug posit cost-effect review icer therefor commun potenti major
budget impact well-manag could lead inappropri restrict access
oncolog posit strong price power could begin erod among oral therapi
seen differ trend price power differ therapeut area drug oncolog
typic hold strong price power convers diabet hit signific media
pressur high-reb area out-of-pocket cost high patient hit
high list price increas even net price remain afford diabet also area
seen drug price pressur drug merck januvia johnson johnson
invokana insulin lilli novo sanofi face unpreced price pressur
note oncolog drug price power partli root fact peopl scare
diseas need best treatment high england give extra weight cost-effect
ratio end life medicar oncolog protect class new treatment need
cover anoth market best option one patient may anoth
case depend drug side effect impact patient life patient willing
take risk tri gain life extens howev think competit landscap
bring greater manag oncolog drug especi oral drug purview pbm
pharmaci benefit side equat surpris
manag cost oncolog oral drug side five year certain market
competit could begin increas think btk market -- includ
incumb imbruvica astra improv calquenc beigen newli approv brukinsa -- area
price pressur could develop
head-to-head studi could critic formulari posit
firm see hold higher price risk partli lack cost effect
humira howev icer highlight oral jak inhibitor rinvoq cost effect rel
humira head-to-head studi gave icer confid conclus firm
autoimmun diseas work head-to-head data like gilead filgotinib versu humira
johnson johnson tremfya versu novarti cosentyx note head-to-head studi
done partli ethic landscap shift -- case longer ethic put
patient placebo head-to-head studi right thing payor patient
accord indirect cross-trial comparison drug done elig
requir endpoint similar still lead new drug hit rebat wall anyway
page
drug effect impact moat valuat esg risk februari import disclosur end report
head-to-head studi seem critic combat drug rebat wall accord
drug better humira one indic pbm committe say pbm
prefer humira indic even though budget pressur prefer
indic bundl rebat word drug show head-to-head superior drug
prefer humira
safeti bigger role effect less dire diseas
see gilead hold lower price risk hiv hepat drug gener appear cost
effect given filgotinib potenti best-in-class safeti among jak inhibitor could also play role
cost effect encourag solid uptak gave exampl acut migrain
situat safeti play key role cost effect even though triptan surfac look
effect novel oral cgrp migrain deadli diseas safeti gain weight
analysi lead physician enthusiasm around new oral cgrp area like oncolog
clinic situat dire much effect think ra market
could sensit posit safeti differenti give gilead filgotinib abil
penetr market despit later entrant
diseas prior treatment matter new drug reimburs
effect gene therapi could face headwind competit payor indigest
sma see potenti price pressur novel treatment come market treatment option
grow rapidli chronic spinal column inject spinraza one-tim gene
therapi novarti zolgensma potenti cheaper oral therapi roch risdiplam could launch
roch firm see gener hold low price risk histori respons
price even novel drug roch comment risdiplam price underwhelm
perhap alter price dynam market icer analysi zolgensma price near
threshold mean million price tag look justifi spinraza -- annual
mainten cost -- well maximum annual price tag icer saw justifi even
though zolgensma price could fair think abil price oral drug easi manufactur
administ current standard could creat price pressur market
expect spinraza consensu
rare diseas player biomarin gener see portfolio hold low price risk ultra-orphan
rare diseas typic scrutin cost effect due small number patient life-
save natur overal low cost societi biomarin manag say payor
recept potenti price hemophilia gene therapi val-rox like launch later year
million million year think justifi given fact current chronic
prophylaxi treatment cost averag roughli annual biomarin data
four-year efficaci val-rox icer hope assess avail
biomarin hemophilia gene therapi val-rox midyear note one-tim treatment
gener good deal current therapi expens case hemophilia think icer
upcom review val-rox could posit also note gene therapi player bio
wrap downstream cost save price new medicin look five year
page
drug effect impact moat valuat esg risk februari import disclosur end report
seem consist biomarin approach icer consid cost off-set current gene
therapi pay chronic treatment annual basi remaind patient
life reason split innov introduc new one-tim gene therapi
societi also seem consist five-year approach biomarin price strategi
howev whether payor abl manag short-term shock near-term high price
anoth question particularli midrang employ sometim stop-loss
reinsur come payment scheme spread cost time difficult public
percept price also impact million novarti sma gene therapi zolgensma
sound high regardless cost effect note success could depend mani
gene therapi treatment approv given year start see number launch --
orphan drug past decad -- pbm could come hard price pressur new
gene therapi launch icer follow gene therapi near term
cure say respons get right get patient system
tri squeez revenu gene therapi expens less cure price could
overal icer summari report mix price support current drug
exhibit summar major icer analys high-profil drug coverag
univers overal studi support cost effect current drug sever studi
suggest drug price cost effect
page
drug effect impact moat valuat esg risk februari import disclosur end report
exhibit icer histori cost-effect determin show mix result drug firm
discount price dupix cost-effect price
icer see car-t cell therapi hold net health benefit cost effect despit afford access
issu kymriah per qali gain pediatr wac yescarta dlbcl
wac
effect well icer threshold price achiev per qali list price
drug could place excess cost burden healthcar system icer set value-bas price benchmark
discount wac
icer recommend value-bas price benchmark around per year discount weight
averag cost three patient popul
prophylaxi cost inhibitor patient rang million make hemlibra price look
afford icer calcul value-bas price benchmark hemlibra treatment cost-sav offer
addit benefit bpa bypass agent prophylaxi
aimovig ajovi achiev rang assum net price patient fail prevent
therapi cost-effect rang aimovig given discount keep list
price drug
tysabri ocrevu look cost-effect peer high-efficaci treatment similar price list price
per qali threshold roughli ocrevu look cost effect rrm ppm
value-bas price would requir indic cost-effect
use bigger rang adjust rare diseas icer found price
reason still high use rang unless treat year old hard diagnos
icer implement new system better account benefit one-tim treatment
xarelto vascepa amarin
icer deem drug cost effect icer still issu afford alert high number patient
need treatment budget impact treat third patient would cost roughli billion xarelto even
vascepa due major patient recommend therapi
icer deem rybelsu cost-effect discount similar level victoza annual price hit cost per qali rang
threshold would saw evid rybelsu offer net health benefit
januvia victoza jardianc
hypothet all-or regimen review show qali improv extra translat extra
per qali treatment longer cost-effect price exceed slightli sovaldi
list price product well within cost-effect threshold roughli annual
net price estim per month prostat cancer therapi per
repatha praluent
repatha cost-effect price rang icer per qali threshold praluent
set higher due signific surviv benefit net price around icer set
valu praluent high-risk patient higher level use determin price
express script agreement icer therefor see praluent cost effect recent price view
repatha similar therapi similar price lack surviv benefit readthrough clinic trial hold back
page
drug effect impact moat valuat esg risk februari import disclosur end report
exhibit continu icer histori cost-effect determin show mix result drug firm
cost effect
price amyloidosi drug deem high cost per qali million tegsedi per
qali onpattro
mar-
icer conclud asthma biolog therapi need least price cut list price cost
effect follow nucala report similar conclus compar nucala list price
roughli cost standard care advair
massiv discount would need list price hit rang therapi second
third-lin treatment
icer see per qali activ spm icer give value-bas price benchmark analysi
overal multipl sclerosi drug price well north cost-effect rang would need least discount list
price achiev per qali threshold
may-
icer set value-bas price benchmark rang zolgensma lower
pricetag spinraza would requir price repres discount list price
opdivo multipl tki bi
list price long-term cost effect tki per qali impli drug fit within
rang without discount list price cost per qali tecentriq appli
keytruda includ broader popul opdivo includ broader popul
although data quit date point cost-effect like improv sinc public surviv data
first-lin lung cancer keytruda
updat analysi use net price drug borderlin cost-effect either
per qali enbrel humira cost-effect new therapi nv
cosentyx taltz oral drug otezla
draft
assum net price rinvoq match humira net price averag discount jak rinvoq
threshold compar humira treatment cost effect ratio rinvoq humira would
per qali net price rinvoq around annual would enough support cost-
effect per qali threshold icer enough data comment cost
effect olumi xeljanz head-to-head data humira icer deem humira cost
effect along novel treatment
lynparza seen cost-effect recurr brca-mut patient net price per month
drug -- well lynparza mainten set -- would requir discount list price
cost-effect howev addit overal surviv data sinc analysi improv cost-effect
therapi
drug benefit patient take triptan accord icer analysi would need price
roughli year cost-effect per qali threshold feb final review also
take account delay benefit patient could swing three therapi posit review ubrelvi
per qali could improv per qali threshold discount dose list price taken
page
drug effect impact moat valuat esg risk februari import disclosur end report
